Smoking among hospitalized patients: A multi-hospital cross-sectional study of a widely neglected problem.
Cristina Martínez, Marcela Fu, Yolanda Castellano...
https://pubmed.ncbi.nlm.nih.gov/31516433Actively Recruiting
Phase 4
Age: 18Years +
All Genders
ID06254001
Effectiveness of Combined Treatment of Bupropion and Nicotine Replacement Therapy in Hospitalized Subjects With Active Smoking in a Reference Center
Led by National Institute of Respiratory Diseases, Mexico · Updated on 2024-02-23
134
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Tobacco smoking continues to be a leading cause of death worldwide, responsible for millions of deaths annually. This research aims to evaluate the effectiveness of combined treatments to help hospitalized active smokers maintain abstinence from smoking. The trial compares the use of nicotine replacement therapy alone versus nicotine replacement therapy combined with bupropion, alongside counseling and behavioral therapy. Participants will be randomly assigned to one of two groups: one receiving nicotine patches with counseling and cognitive behavioral therapy, and the other receiving nicotine patches plus bupropion at doses of 150 mg to 300 mg per day, along with counseling and behavioral therapy. Follow-up visits with a pulmonologist will occur at 3, 6, and 12 months, including pulmonary function tests. During the study, abstinence from smoking will be verified through urine cotinine tests and exhaled carbon monoxide tests at each follow-up. Participants will undergo regular assessments of lung function and receive behavioral support throughout the 12-month period. The main outcome measured is smoking abstinence at 12 months, confirmed by negative cotinine and exhaled carbon monoxide tests.
CONDITIONS
Brief Title
Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Active smokers who have consumed more than 100 cigarettes in their lifetime
- Smoked cigarettes within the last 30 days
- Currently hospitalized
- Provided informed consent
You will not qualify if you...
- Used pharmacological treatment to stop smoking within the last month
- Have contraindications for the study medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - Up to 12 months
Participants receive nicotine replacement therapy with counseling and cognitive behavioral therapy. Some participants also receive bupropion at doses of 150 mg to 300 mg per day in addition to nicotine replacement therapy and counseling.
Follow-up visits at 3, 6, and 12 months with a pulmonologist
Trial Site Locations
Total: 1 location
1
Instituto Nacional de Enfermedades Respiratorias
Mexico City, Mexico, 14080
Actively Recruiting
Loading map...
Research Team
I
IRERI THIRION, DR
R
ROGELIO PEREZ-PADILLA, DR
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Interventions for smoking cessation in hospitalised patients.
Nancy A Rigotti, Carole Clair, Marcus R Munafò...
https://pubmed.ncbi.nlm.nih.gov/22592676Tobacco Cost of Illness Studies: A Systematic Review.
Marshall Makate, Steve Whetton, Robert J Tait...
https://pubmed.ncbi.nlm.nih.gov/30874290